Taken together, these results give proof of the principle that CD31-labeled sciadopitysin NPs might have clinical utility to ameliorate disorders of low bone mass, such as postmenopausal osteoporosis. This evidence concerns the gene PECAM1 and postmenopausal osteoporosis.